Circulating Levels of MicroRNAs in Hypertrophic Cardiomyopathy: The Relationship With Left Ventricular Hypertrophy, Left Atrial Dilatation and Ventricular Depolarisation-Repolarisation Parameters.


Journal

Heart, lung & circulation
ISSN: 1444-2892
Titre abrégé: Heart Lung Circ
Pays: Australia
ID NLM: 100963739

Informations de publication

Date de publication:
Feb 2022
Historique:
received: 18 08 2020
revised: 31 12 2020
accepted: 25 04 2021
pubmed: 6 6 2021
medline: 18 1 2022
entrez: 5 6 2021
Statut: ppublish

Résumé

MicroRNAs are small, endogenous, non-coding RNAs that regulate the expression of many genes. It has recently been shown that circulating microRNAs may be biomarkers of hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy (HCM). To determine whether circulating levels of microRNAs involved in HCM are associated with electrocardiographic and echocardiographic parameters. This study enrolled 20 patients with familial HCM and 20 blood donors. Peripheral serum levels of miR-29a-3p, miR-199a-5p and miR-451a were assessed by quantitative real-time polymerase chain reaction and compared with levels in the control group. Whether circulating levels of miRNAs in HCM patients correlated with electrocardiographic and echocardiographic parameters was also assessed. Median circulating levels of miR-29a and miR-451a were significantly higher in HCM than the control group. Median miR-199a levels did not differ between groups. However, circulating levels of miR-199a negatively correlated with corrected QT duration (Bazett formula). Median miR-29a levels positively correlated with QRS duration. In addition, circulating levels of miR-29a correlated with maximal wall thickness, left ventricular mass index and left atrial volume index. The data suggested that serum levels of miR-29a and miR-451a were significantly increased in HCM patients. As the circulating level of miR-29a correlated with QRS duration, left ventricular hypertrophy and left atrial dilatation, the serum miR-199a level negatively correlated with corrected QT duration. These miRNAs may be seen as potential biomarkers for further research in HCM pathophysiology.

Sections du résumé

BACKGROUND BACKGROUND
MicroRNAs are small, endogenous, non-coding RNAs that regulate the expression of many genes. It has recently been shown that circulating microRNAs may be biomarkers of hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy (HCM).
OBJECTIVE OBJECTIVE
To determine whether circulating levels of microRNAs involved in HCM are associated with electrocardiographic and echocardiographic parameters.
METHODS METHODS
This study enrolled 20 patients with familial HCM and 20 blood donors. Peripheral serum levels of miR-29a-3p, miR-199a-5p and miR-451a were assessed by quantitative real-time polymerase chain reaction and compared with levels in the control group. Whether circulating levels of miRNAs in HCM patients correlated with electrocardiographic and echocardiographic parameters was also assessed.
RESULTS RESULTS
Median circulating levels of miR-29a and miR-451a were significantly higher in HCM than the control group. Median miR-199a levels did not differ between groups. However, circulating levels of miR-199a negatively correlated with corrected QT duration (Bazett formula). Median miR-29a levels positively correlated with QRS duration. In addition, circulating levels of miR-29a correlated with maximal wall thickness, left ventricular mass index and left atrial volume index.
CONCLUSIONS CONCLUSIONS
The data suggested that serum levels of miR-29a and miR-451a were significantly increased in HCM patients. As the circulating level of miR-29a correlated with QRS duration, left ventricular hypertrophy and left atrial dilatation, the serum miR-199a level negatively correlated with corrected QT duration. These miRNAs may be seen as potential biomarkers for further research in HCM pathophysiology.

Identifiants

pubmed: 34088630
pii: S1443-9506(21)00500-X
doi: 10.1016/j.hlc.2021.04.019
pii:
doi:

Substances chimiques

Circulating MicroRNA 0
MIRN29a microRNA, human 0
MIRN451 microRNA, human 0
MicroRNAs 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

199-206

Informations de copyright

Copyright © 2021 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.

Auteurs

Mehmet Rasih Sonsöz (MR)

Department of Cardiology, Basaksehir Pine and Sakura City Hospital, Istanbul, Turkey. Electronic address: mrsonsoz@gmail.com.

Mustafa Yilmaz (M)

Department of Cardiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Erdem Cevik (E)

Department of Cardiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Huseyin Orta (H)

Department of Cardiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Ahmet Kaya Bilge (AK)

Department of Cardiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Ali Elitok (A)

Department of Cardiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Imran Onur (I)

Department of Cardiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Evrim Komurcu-Bayrak (E)

Department of Genetics, Aziz Sancar Institute of Experimental Medicine and Department of Medical Genetics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH